{
  "_originalData": {
    "identity": {
      "bacteriumName": "Bacillus sp.",
      "lastUpdated": "2024-07-30",
      "clsiCategory": "additional_bacteria",
      "classification": {
        "gramStain": "Gram-positive",
        "morphology": "rods",
        "notes": [
          "Spore-forming"
        ]
      },
      "strainDetails": [
        {
          "type": "Species",
          "value": "Bacillus subtilis"
        },
        {
          "type": "Species",
          "value": "Bacillus cereus"
        }
      ],
      "biochemicalTests": "Gram-positive rods, often large and in chains, spore-forming (aerobic), catalase +, motility variable (B. anthracis is non-motile, others are motile)."
    },
    "clinicalProfile": {
      "summary": "Bacillus subtilis and other Bacillus sp. occasionally cause systemic infections, but often are a culture contaminant. Bacillus sp. are etiologic in IV line infections in patients with hematologic malignancies, contamination of the fluid used to transport organs for transplantation, endophthalmitis, toxin-induced fulminant liver failure, soft tissue infection in injection drug users.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Food poisoning",
          "description": "some strains produce enterotoxin that causes diarrhea"
        },
        {
          "syndromeName": "IV line infections"
        },
        {
          "syndromeName": "Endophthalmitis"
        },
        {
          "syndromeName": "Toxin-induced fulminant liver failure"
        },
        {
          "syndromeName": "Soft tissue infection"
        }
      ],
      "highRiskPopulations": [
        "Patients with hematologic malignancies",
        "Injection drug users",
        "Organ transplant recipients"
      ]
    },
    "resistanceProfile": {
      "clinicalAlerts": [
        {
          "alertTitle": "Beta-lactam Resistance",
          "details": "B. cereus often resistant to all beta-lactams other than carbapenems"
        },
        {
          "alertTitle": "Carbapenem Resistance",
          "details": "resistance to imipenem and meropenem has been encountered"
        },
        {
          "alertTitle": "Clindamycin Resistance",
          "details": "Susceptibility to Clindamycin (or other agents used) should be confirmed, as resistance does occur"
        }
      ]
    },
    "treatment": {
      "generalNotes": [
        "No specific treatment for food poisoning."
      ],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "condition": "Bloodstream infection or invasive disease"
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "Vancomycin",
                  "dose": "15-20 mg/kg",
                  "route": "IV",
                  "frequency": "q8-12h",
                  "comments": "to achieve preferred target AUC 400-600 µg/mL x hr (see vancomycin AUC dosing calculator; alternative is trough level of 15-20 µg/mL)"
                },
                {
                  "drugName": "Clindamycin",
                  "dose": "600mg",
                  "route": "IV",
                  "frequency": "q8h"
                }
              ]
            },
            {
              "preference": "Alternative",
              "drugs": [
                {
                  "drugName": "Fluoroquinolone"
                },
                {
                  "drugName": "Imipenem"
                }
              ]
            }
          ]
        }
      ]
    },
    "additionalInformation": {
      "drugSpecificPearls": [
        {
          "drugName": "Linezolid",
          "pearl": "in vitro activity"
        },
        {
          "drugName": "Daptomycin",
          "pearl": "in vitro activity"
        },
        {
          "drugName": "Tetracycline",
          "pearl": "in vitro activity"
        },
        {
          "drugName": "macrolides",
          "pearl": "in vitro activity"
        }
      ],
      "guidelineReferences": [
        {
          "source": "Trends Microbiol.",
          "citation": "2021;29:458-471"
        },
        {
          "source": "J Antimicrob Chemother",
          "citation": "60:555, 2007"
        },
        {
          "source": "Intern Med",
          "citation": "51:2733, 2012"
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.362Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Bacillus sp."
    },
    "aliases": {
      "sources": [
        "identity.aliases",
        "aliases"
      ],
      "value": []
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2024-07-30"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram-positive",
        "morphology": "rods",
        "notes": [
          "Spore-forming"
        ]
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Bacillus subtilis and other Bacillus sp. occasionally cause systemic infections, but often are a culture contaminant. Bacillus sp. are etiologic in IV line infections in patients with hematologic malignancies, contamination of the fluid used to transport organs for transplantation, endophthalmitis, toxin-induced fulminant liver failure, soft tissue infection in injection drug users.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Food poisoning",
          "description": "some strains produce enterotoxin that causes diarrhea"
        },
        {
          "syndromeName": "IV line infections"
        },
        {
          "syndromeName": "Endophthalmitis"
        },
        {
          "syndromeName": "Toxin-induced fulminant liver failure"
        },
        {
          "syndromeName": "Soft tissue infection"
        }
      ],
      "highRiskPopulations": [
        "Patients with hematologic malignancies",
        "Injection drug users",
        "Organ transplant recipients"
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "clinicalAlerts": [
        {
          "alertTitle": "Beta-lactam Resistance",
          "details": "B. cereus often resistant to all beta-lactams other than carbapenems"
        },
        {
          "alertTitle": "Carbapenem Resistance",
          "details": "resistance to imipenem and meropenem has been encountered"
        },
        {
          "alertTitle": "Clindamycin Resistance",
          "details": "Susceptibility to Clindamycin (or other agents used) should be confirmed, as resistance does occur"
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": []
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile",
      "laboratory"
    ],
    "value": {}
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}